Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.

Author:
  • Jia-Jing Lee
  • Amy Y M Au
  • Theodoros Foukakis
  • Michela Barbaro
  • Nimrod Kiss
  • Roderick Clifton-Bligh
  • Johan Staaf
  • Åke Borg
  • Leigh Delbridge
  • Bruce G Robinson
  • Göran Wallin
  • Anders Höög
  • Catharina Larsson
Publishing year: 2008
Language: English
Pages: 801-815
Publication/Series: Endocrine-Related Cancer
Volume: 15
Issue: 3
Document type: Journal article
Publisher: Society for Endocrinology

Abstract english

Anaplastic thyroid cancer (ATC) is a rare but highly aggressive disease with largely unexplained etiology and molecular pathogenesis. In this study, we analyzed genome-wide copy number changes, BRAF (V-raf sarcoma viral oncogene homolog B1) mutations, and p16 and cyclin D1 expressions in a panel of ATC primary tumors. Three ATCs harbored the common BRAF mutation V600E. Using array-comparative genomic hybridisation (array-CGH), several distinct recurrent copy number alterations were revealed including gains in 16p11.2, 20q11.2, and 20q13.12. Subsequent fluorescence in situ hybridization revealed recurrent locus gain of UBCH10 in 20q13.12 and Cyclin D1 (CCND1) in 11q13. The detection of a homozygous loss encompassing the CDKN2A locus in 9p21.3 motivated the examination of p16 protein expression, which was undetectable in 24/27 ATCs (89%). Based on the frequent gain in 11q13 (41%; n=11), the role of CCND1 was further investigated. Expression of cyclin D1 protein was observed at varying levels in 18/27 ATCs (67%). The effect of CCND1 on thyroid cell proliferation was assessed in vitro in ATC cells by means of siRNA and in thyroid cells after CCND1 transfection. In summary, the recurrent chromosomal copy number changes and molecular alterations identified in this study may provide an insight into the pathogenesis and development of ATC.

Keywords

  • Cancer and Oncology

Other

Published
  • ISSN: 1479-6821
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90